Biotech | November 20, 2021
Oravax and Genomma JV to commercialise Covid-19 vaccine in Mexico and Latam
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
First-of-its-kind Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics
The US $ 192.5 mn US government contract will help fund the centre of excellence to boost the domestic supply of critically needed laboratory plastics
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent
The injunction order has been passed against Natco Pharma, Torrent Pharmaceuticals, Eris Lifesciences and Windlas Biotech
Expertise in exosomes isolation and characterization will drive innovation in this field
This approval of shelf-life extension was based on the availability of additional stability data, which was submitted to CDSCO
This is the eighth Covid-19 vaccine to receive Emergency Use Listing
It is the first integrated digital PCR solution ideal for oncology, cell and gene therapy development
Subscribe To Our Newsletter & Stay Updated
